Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma

Clinical Oncology

Volumn 8, Issue 6, 1996, Pages 346-352

  Gibbs, S J ^a   Plowman, P N ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; CYPROTERONE ACETATE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GESTAGEN; HYDROCORTISONE; NILUTAMIDE;

ADVANCED CANCER; CASTRATION; ENDOCRINE FUNCTION; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; CLINICAL TRIALS; ESTROGENS, NON-STEROIDAL; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 0030431371     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(96)80073-2     Document Type: Review

References (44)

1. Huggins C, Hodges CV. Studies on prostate cancer: Effects of castration, of oestrogen, and of androgen injection on serum phosphatase in metastatic cancer of the prostate. Cancer Res 1941;1:293-7.
2. Kaisary AV, Tyrell CJ, Peeling WB, et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate carcinoma. Br J Urol 1991;67:502-8.
3. McLeod DG. Antiandrogenic drugs. Cancer 1993;71:1046-9.
4. Denis L. Prostate cancer: Primary hormonal treatment. Cancer 1993;71:1050-7.
5. Geller J, Albert J, Loza D, et al. Dihydrotestosterone concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978;46:440-4.
6. Schally AV, Comaru-Schally AM, Gonzalez-Barcena D. Present state of agonistic and antagonistic analogs of LHRH in the treatment of advanced prostate cancer. Biomed Pharmacother 1992;46:71.
7. Gonzalez-Barcena D, Cardenas-Carnejo I, Vadillo-Buenfil M, et al. Luteinising hormone releasing hormone antagonist Cetrorelix as primary single therapy in patients with advanced prostate cancer and paraplegia due to metastatic invasion of the spinal cord. Urology 1995;45:275-81.
8. Gonzalez-Barenca D, Vadillo-Buenfil M, Gomez-Orta F, et al. Responses to the antagonistic analog of LHRH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994;24:84-92.
9. Leuprolide Study Group. Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281-6.
10. Fass D, Steinfield A, Brown J, et al. Radiotherapeutic prophylaxis of estrogen-induced gynaecomastia: A study of late sequela. Int J Radiat Oncol Biol Phys 1986;12:407-8.
11. Knuth UA, Hano R, Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 1984;59:963-9.
12. Scott WW, Schirmer HK. A new progestational steroid effective in the treatment of prostate cancer. Trans Am Assoc Genitourin Surg 1966;58:54-61.
13. Pavone-Macaluso M, De Voogt HJ, Viggiano G, et al. Comparison of diethylstilboestrol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostatic cancer. J Urol 1986;136:624-31.
14. Hepatic reactions with cyproterone acetate (Cyprostat, Androcur). Curr Prob Pharmacovigilence. 1995;(Feb):21.
15. Eaton AC, McGuire N. Cyproterone acetate in treatment of post-orchidectomy hot flushes. Lancet 1983;ii:1336-7.
16. De Voogt HJ, Klijn JGM, Studer U, et al. Orchidectomy versus buserelin in combination with cyproterone acetate, for two weeks or continuously, in the treatment of metastatic prostate cancer: Preliminary results of EORTC trial 30843. J Steroid Biochem Mol Biol 1990;37:965-71.
17. Boccon-Gibod L, Laudet MH, Dugue MA, et al. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by LHRH analogs in the treatment of metastatic carcinoma of prostate. Eur Urol 1986;12:400-02.
18. Geller J. Megestrol acetate plus low dose oestrogen in the management of advanced prostate cancer. Urol Clin North Am 1991;18:883-91.
19. Venner PM, Klotz PG, Klotz LH, et al. Megestrol acetate plus minidose diethylstilboestrol in the treatment of carcinoma of the prostate. Semin Oncol 1988;15(Suppl):62-7.
20. Geller J, Albert J, Yen SSC. Treatment of advanced cancer of the prostate with megestrol acetate. Urology 1978;12:537-41.
21. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flushes. N Engl J Med 1994;331:347-52.
22. Ponder BA, Shearer RJ, Pocock RD, et al. Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. Br J Cancer 1984;50:757-63.
23. Plowman PN, Perry LA, Chard T. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br J Urol 1987;59:255-7.
24. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-91.
25. Andriole G, Lieber M, Smith J, et al. Treatment with finateride following radical prostatectomy for prostate cancer. Urology 1995;45:491-7.
26. Fair WR, Presti JC, Sogani P, et al. Multicenter randomised, double-blind, placebo-controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1991;145:317A.
27. Brawley DW, Thompson IM. Chemoprevention of prostate cancer. Urology 1994;43:594-9.
28. Gaillard-Moguilewsky M, de Gery A, Ulmann A. Pharmacology of nilutamide. Cancer 1993;72:3828-9.
29. Decesni AU, Boccardo F, Guarmeri D, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991;146:377-81.
30. Bertagna C, de Gery A, Hucher M, et al. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostate cancer: A meta-analysis of seven randomised double blind trials. Br J Urol 1994;73:396-402.
31. Prout GR, Keating MA, Griffin PP. et al. Long term experience with flutamide in patients with prostatic carcinoma. Urology 1989;34:37-45.
32. Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic carcinoma: A controlled prospective study. Br J Urol 1988;61:140-2.
33. De Kernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone refractory metastatic prostate cancer. Urology 1988;31:312-7.
34. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of Leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
35. Denis LJ, Carneiro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: A Phase 3 EORTC trial (30853). Urology 1993;42:119-30.
36. Prostate Cancer Trialists' Collaborative Group. Maximal androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.
37. Blackledge G. Casodex-mechanisms of action and opportunities for usage. Cancer 1993;72:3830-3.
38. Waymont B, Blackledge G, Tyrell CJ, et al. Efficacy and safety of the nonsteroidal antiandrogen Casodex in early clinical trials for advanced prostate cancer. Br J Cancer 1990;62:400.
39. Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide each in combination with LHRH analogue therapy in patients with advanced prostate cancer. Urology 1995;45:745-2.
40. Labrie F, Dupont A, Belanger A. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 1983;4:579-94.
41. Small EJ, Schellhammer P, Venner P, et al. A double blind assessment of antiandrogen withdrawal from Casodex or Eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer. Proc Am Soc Clin Oncol 1996;15:255 Abstract 658.
42. Wehbe TW, Wehbe P, Akerley W, et al. PSA response to Megace withdrawal in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1996;15:257 Abstract 667.
43. Shearer RJ, Davies JH, Gelister JSK, et al. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992;69:521-4.
44. Dearnaley DP. Radiotherapy for prostate cancer: The changing scene [editorial]. Clin Oncol 1995;7:147-50.